Trial register facet
Trial records reported in 2025
59 records with a recorded report or completion year of 2025.
Showing 0 records on this page
Records
59 documents · page 1 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| ACHIEVE-1 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ACHIEVE-1-BODY-COMPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-1-QOLprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-1-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2025 | Not rated |
| ACHIEVE-2-ADHERENCEprogramme record | Orforglipron | Phase 3 | Reported | Observational | — | 2025 | Very low |
| ACHIEVE-2-BIOMARKERprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ACHIEVE-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| ATTAIN-1 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Moderate |
| ATTAIN-1-REGIONAL-JPprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-2 | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ATTAIN-2-ELDERLYprogramme record | Orforglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ATTAIN-2-OLEprogramme record | Orforglipron | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| ECNO-PH3-CN-OBESITY | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 664 | 2025 | Low |
| ECNO-PH3-CN-OBESITY-BODY-COMPprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-OBESITY-REGIONAL-JPprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-T2D | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Not rated |
| ECNO-PH3-CN-T2D-ELDERLYprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-OLEprogramme record | Ecnoglutide | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| ECNO-PH3-CN-T2D-REGIONAL-CNprogramme record | Ecnoglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| ESSENCE | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 1,197 | 2025 | Moderate |
| ESSENCE-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| ESSENCE-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
page 1 of 3